The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers

Table 16

Expression (%) of costimulatory and LNH molecules on mDC1s in the blood of women with LLABCs undergoing NAC. Baseline (B) levels in LLABCs versus completion of chemotherapy (CC) levels in different responders.

Study group comparisons		CD40	CD80	CD83	CD86	CD197
Good pathological responders (GPR: )	B (%)	40.60 ± 10.00	2.02 ± 1.30	4.45 ± 0.75	40.97 ± 14.00	31.29 ± 8.00
	CC (%)	43.13 ± 10.00	3.83 ± 2.00	3.71 ± 1.70	28.66 ± 7.00	48.34 ± 14.00
	B versus CC; ( value)	NS	NS	NS	NS	NS
	CC versus HFDs; ( value)	NS	NS	NS	NS	NS
Poor pathological responders (PPRs: )	B (%)	26.80 ± 10.00	1.48 ± 0.50	2.98 ± 2.00	21.37 ± 10.00	22.73 ± 6.00
	CC (%)	16.80 ± 8.00	2.29 ± 1.20	4.47 ± 1.80	6.81 ± 6.00	13.83 ± 5.00
	B versus CC; ( value)	NS	NS	NS	NS	NS
	CC versus HFDs; ( value)	0.001	NS	NS	0.001	NS
Post-NAC GPR versus PPR	GPR CC versus PPR CC; ( value)	0.005	NS	NS	0.004	0.003

LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; GPRs: complete or >90% reduction of tumour cell mass; PPRs: no or ≤90% reduction of tumour cell mass; HFDs: healthy female donors; NS: nonsignificant; statistically significant.